Grail (NASDAQ:GRAL) Stock Price Up 8.1% – What’s Next?

Grail, Inc. (NASDAQ:GRAL) shares were up 8.1% during mid-day trading on Monday . The stock traded as high as $18.99 and last traded at $18.92. Approximately 248,407 shares were traded during mid-day trading, a decline of 77% from the average daily volume of 1,057,470 shares. The stock had previously closed at $17.50.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. Morgan Stanley assumed coverage on Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 price objective on the stock. Wolfe Research initiated coverage on shares of Grail in a research report on Friday, November 15th. They set a “peer perform” rating on the stock. Finally, Guggenheim started coverage on shares of Grail in a report on Thursday, October 17th. They issued a “neutral” rating for the company.

Grail Trading Up 8.5 %

The stock has a 50 day simple moving average of $14.36.

Insider Buying and Selling at Grail

In other news, CEO Robert P. Ragusa sold 123,454 shares of the firm’s stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the sale, the chief executive officer now directly owns 612,661 shares in the company, valued at $8,589,507.22. This trade represents a 16.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Chun R. Ding purchased 7,629 shares of Grail stock in a transaction that occurred on Tuesday, October 1st. The shares were bought at an average price of $13.52 per share, with a total value of $103,144.08. Following the transaction, the insider now owns 3,503,655 shares in the company, valued at approximately $47,369,415.60. The trade was a 0.22 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 58,829 shares of company stock valued at $757,298.

Grail Company Profile

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.